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REDUCING IMPLANTABLE
DEVICE INFECTIONS

Surgical site infections can be devastating to
patients; consequences can include sepsis, limb
loss and even death. In addition, these infections
can be costly to our nation’s healthcare system,
adding an average of 4.3 days to hospital stays
and $10,497 per patient to the overall cost.
“Although overall infection rates are very low—
currently, only about one percent of recipients
develop a CIED-related infection—they are bad
experiences for patients, potentially even fatal,”
says Dr. Greenspon.
EVEN AS JEFFERSON RESEARCHERS HELP ADVANCE MEDICAL
care by developing wholly new treatments,
methods and tools, they are also working hard to
reduce complications associated with procedures
performed by tertiary care centers across the country.
Post-procedure infections, in particular, can be a
pernicious and costly problem. Clinician-scientists
throughout the Jefferson system are pursuing clinical
trials that aim to address the problem.
For example, Arnold J. Greenspon, MD, professor
of medicine and director of the Jefferson Cardiac
Electrophysiology Laboratory, is working to
address the problem of infections associated with
cardiac implantable electronic devices (CIEDs),
such as pacemakers, implantable cardioverterdefibrillators and cardiac resynchronization therapy
devices. While any medical device or product
implanted in the human body can become infected,
hospitals across the country have seen the rate
of CIED infection grow faster than that of other
types of device implantations. These patients must
return to the hospital to have the device removed
and to undergo antibiotic treatment. Subsequently,
they must have a replacement implanted.
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Moreover, a study he co-authored last year
found that CIED infections are quite costly—
with expenditures for Medicare fee-for-service
beneficiaries ranging from $22,000 to $77,000
per case.

Studies to Prevent CIED Infections
For those reasons, Dr. Greenspon has been
collaborating in a series of research studies
seeking to define the factors that cause these
infections to develop. He has also partnered
in an array of multi-center trial approaches for
reducing the rate of CIED infection. A report on
the most recent of those trials, centering on an
absorbable, antibiotic-eluting mesh “envelope” for
the CIED, was published recently in New England
Journal of Medicine. It showed that use of the
antibacterial envelope resulted in a significantly
lower incidence of major CIED infections than
standard-of-care infection-prevention strategies
alone, without notable added complications.
Now, Dr. Greenspon is collaborating with
researchers at Vanderbilt University on a trial with

patients at high-risk for CIED infection. It will seek
to determine if use of the antibacterial envelope
with an additional, post-procedure application of
systemic antibiotics will further reduce incidence
of infection.

Compared to patients receiving standard
dressing, the negative pressure therapy resulted in
significantly fewer wound infections (9 percent),
reduced patient reoperation and readmission
and an average savings of $6,045 per patient.

Reducing Infections in Vascular Procedures

The second study, now in progress, is testing
negative pressure therapy for surgical wounds
following lower-leg amputation. Wound
complications in this setting have been reported
as high as 34 percent nationwide. This multicenter trial aims to enroll 440 patients who will
undergo above- or below-knee amputations
at one of six participating medical centers in
the United States and Europe. Results from the
study are expected to be available in late 2021.

Paul DiMuzio, MD, MBA, William M. Measey
Professor of Surgery and director of Jefferson’s
Division of Vascular and Endovascular Surgery,
has led two studies on the use of a “negative
pressure therapy” to reduce infections at the
incision site in vascular surgical procedures. Both
studies compare standard surgical dressings with
the PREVENA™ Dressing Kit, a negative pressure
dressing that continuously drains exudates from
surgical incisions, which is applied immediately in
the operating room.
The first study, published last year in the Journal
of Vascular Surgery, focused on vascular groin
incisions, where complications rates are as
high as 44 percent, nationally. The randomized
controlled trial focused on 119 femoral artery
incisions considered high-risk for complications.

“We are particularly excited about the potential
for reducing wound infections for this patient
population, many of whom are suffering from
peripheral vascular disease, diabetes or heart
failure and are particularly vulnerable to postsurgical infections," says Dr. DiMuzio. 
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